(Q34325164)

1 August 2017

1 reference

title

Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy (English)

1 reference

1 August 2017

0 references

Leslie Citrome

1

0 references

language of work or name

English

0 references

publication date

28 January 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

30

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

114-126

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-013-0006-7

1 August 2017

exact match

0 references

cites work

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

Lurasidone in schizophrenia: new information about dosage and place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0006-7

10.1007/S12325-013-0006-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1029649256

0 references

1 reference